Bayer Invests in US Gene-Editing Company Metagenomi
November 12 2020 - 8:06AM
Dow Jones News
By Cecilia Butini
Bayer AG said Thursday that it has invested in U.S.-based
company Metagenomi, which focuses on gene-editing techniques in
order to advance therapies in oncology and genetics diseases.
The German chemical and pharmaceutical conglomerate has co-led a
$65 million series A financing for Metagenomi through its
investment arm Leaps by Bayer together with Humboldt Fund, the
companies said in a joint statement.
"Capital raised during this round will enable Metagenomi to
accelerate the expansion of its gene editing systems for potential
therapeutic use. In addition, Metagenomi will advance research and
preclinical validation for its own pipeline," the companies
said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
November 12, 2020 07:51 ET (12:51 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Sep 2023 to Sep 2024